title: High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
abstract: Six patients with multiple myeloma and chronic renal insufficiency (serum creatinine >3.0 mg/dl), including four on dialysis, received high-dose busulfan and cyclophosphamide (BUCY) followed by autologous peripheral stem cell transplantation. Peripheral blood stem cells were collected after priming with cyclophosphamide, etoposide and G-CSF. Patterns of engraftment and toxicities were not apparently different from those seen in myeloma patients with normal renal function. There was one toxicity-related death, resulting from a massive spontaneous subdural hematoma. One patient died of disease progression 6 months after transplant, while the remaining four patients are alive and free of myeloma progression 6 to 39 months after high-dose therapy. Two of these patients have remained in complete remission for 28 and 39 months. Our experience suggests that high-dose therapy with BUCY and autologous peripheral blood stem cell rescue is feasible in patients with multiple myeloma and renal failure.
authors.affiliation: Division of Bone Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612, USA.
authors.forename: O F
authors.initials: OF
authors.lastname: Ballester
authors.forename: R
authors.initials: R
authors.lastname: Tummala
authors.forename: W E
authors.initials: WE
authors.lastname: Janssen
authors.forename: K K
authors.initials: KK
authors.lastname: Fields
authors.forename: J W
authors.initials: JW
authors.lastname: Hiemenz
authors.forename: S C
authors.initials: SC
authors.lastname: Goldstein
authors.forename: J B
authors.initials: JB
authors.lastname: Perkins
authors.forename: D M
authors.initials: DM
authors.lastname: Sullivan
authors.forename: R
authors.initials: R
authors.lastname: Rosen
authors.forename: R
authors.initials: R
authors.lastname: Sackstein
authors.forename: P
authors.initials: P
authors.lastname: Zorsky
authors.forename: R
authors.initials: R
authors.lastname: Saez
authors.forename: G J
authors.initials: GJ
authors.lastname: Elfenbein
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D011994:Recombinant Proteins; D051437:Renal Insufficiency / Q000150:complications*; D014182:Transplantation, Autologous
chemical_list: D018906:Antineoplastic Agents, Alkylating; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D002066:Busulfan